ANDY HARRISON

Andy Harrison stands as a pivotal figure in the venture capital landscape, serving as a Managing Partner at Section 32. At this leading firm, co-founded by Google Ventures founder Bill Maris, Harrison plays a crucial role in identifying and nurturing groundbreaking companies that are set to redefine the future of healthcare, life sciences, and technology. His leadership at Section 32 reinforces the firm's commitment to investing in disruptive innovations that address significant global challenges and improve human well-being.

Harrison's investment focus is broad yet deeply specialized, encompassing areas such as biotechnology, digital health, medical devices, and the application of artificial intelligence in healthcare. He seeks out visionary entrepreneurs and companies developing cutting-edge solutions, from novel therapeutics and diagnostics to advanced health tech platforms. His strategic insights help guide these ventures through critical growth stages, leveraging his extensive network and industry expertise to accelerate their success. Section 32, under Harrison's guidance, is particularly interested in companies that demonstrate strong scientific foundations, clear market potential, and the ability to scale their impact.

Before joining Section 32, Andy Harrison built an impressive career marked by significant contributions across both operational and investment roles. He was a key member of the Google Ventures (GV) team, where he worked alongside Bill Maris and led numerous successful investments in the life sciences and healthcare sectors. His tenure at GV solidified his reputation as a discerning investor with a keen eye for transformative technologies. Prior to GV, Harrison honed his investment acumen at Venrock, another top-tier venture capital firm, where he continued to focus on healthcare opportunities. His earlier career also includes valuable operational experience at Genentech, a pioneering biotechnology company. This blend of hands-on industry experience and deep investment expertise provides him with a unique perspective, enabling him to thoroughly evaluate complex scientific and business models.

Throughout his career, Andy Harrison has been associated with numerous impactful investments that have gone on to achieve significant milestones. While specific investment details often remain proprietary, companies like Freenome, GRAIL, Guardant Health, Invitae, and Sana Biotechnology represent the caliber of innovative firms he has supported. These companies are at the forefront of developing advanced diagnostics, precision medicine, and novel therapies, reflecting Harrison's dedication to backing ventures that promise substantial societal benefit and strong financial returns.

As a Managing Partner at Section 32, Andy Harrison continues to shape the future of healthcare and technology investment. His strategic vision, combined with a profound understanding of scientific innovation and market dynamics, positions him as a leading voice in the venture capital community. He remains committed to empowering entrepreneurs who are building the next generation of industry-leading companies, driving progress and delivering tangible value across the globe.